44ktgold's Blog

Latest Media and Entertainment News

• Dragonfly Therapeutics anuncia la aceptación de Celgene como el tercer candidato a medicamento de inmunoterapia TriNKET™ November 13, 2019
  Dragonfly recibirá un pago en licencias de 12 millones de USD y puede optar a recibir posibles logros y regalías sobre las ventas netas. WALTHAM, Massachusetts, 13 de noviembre de 2019 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly" o la "Compañía"), ha anunciado hoy que ha...
• Appel à agir pour sauver le récif : Fabien Cousteau se rend à Cairns pour Seiko November 13, 2019
  SYDNEY, Australie, 13 novembre 2019 /PRNewswire/ -- Seiko a appelé à sortir de l'apathie face au changement climatique. L'horloger japonais a invité à Cairns le défenseur de l'environnement et réalisateur de documentaires, Fabien Cousteau, à titre d'ambassadeur de la marque pour la montre...
• Choice Hotels Announces Pricing of Senior Notes Offering November 13, 2019
  ROCKVILLE, Md., Nov. 13, 2019 /PRNewswire/ -- Choice Hotels International, Inc. (NYSE: CHH) (the "Company"), announced the pricing of senior notes in an aggregate principal amount of $400 million, in an underwritten, registered public offering. The notes will mature in December 2029, will...
• Medicure Announces Commencement of Substantial Issuer Bid November 13, 2019
  WINNIPEG, Nov. 13, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH, OTC: MCUJF), a cardiovascular pharmaceutical company, today announced the commencement of its previously announced substantial issuer bid (the "Offer"), pursuant to which the Company offers to...
• Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes November 13, 2019
  RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 13, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support approval as an adjunct...